10x Genomics (NASDAQ:TXG) Stock Price Expected to Rise, Citigroup Analyst Says

Key Points

• Citigroup raised its 10x Genomics price target from $50 to $60 but maintained a Neutral rating, implying about 1.2% upside from the cited share price.
• 10x Genomics’ latest quarterly loss was narrower than expected, and revenue exceeded forecasts. The company also raised its 2026 revenue outlook to $625 million–$635 million, though production constraints and margin pressure remain challenges.
• Analyst sentiment overall was Hold, with an average price target of $68.07; shares rose 2.1% to $59.28 in Friday trading.

10x Genomics (NASDAQ:TXG - Get Free Report) had its target price boosted by equities researchers at Citigroup from $50.00 to $60.00 in a research note issued on Friday, Benzinga reports. The brokerage currently has a "neutral" rating on the stock. Citigroup's price target points to a potential upside of 1.21% from the company's current price.

A number of other research analysts have also recently weighed in on TXG. Stephens cut shares of 10x Genomics from an "overweight" rating to an "equal weight" rating in a report on Friday, October 23rd. Stifel Nicolaus increased their target price on shares of 10x Genomics from $50.00 to $68.00 and gave the stock a "buy" rating in a research note on Friday. Leerink Partners increased their target price on shares of 10x Genomics from $40.00 to $90.00 and gave the stock a "market perform" rating in a research note on Tuesday, September 29th. UBS Group restated a "neutral" rating and set a $61.00 target price on shares of 10x Genomics in a research report on Friday. Finally, Morgan Stanley upped their price target on 10x Genomics from $40.00 to $70.00 and gave the stock an "equal weight" rating in a report on Monday, October 12th. Five investment analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Hold" and an average target price of $68.07.

10x Genomics Stock Up 2.1%

Shares of NASDAQ TXG traded up $1.22 during midday trading on Friday, reaching $59.28. 4,521,141 shares of the stock were exchanged, compared to its average volume of 3,031,030. The firm has a market cap of $7.72 billion, a price-to-earnings ratio of -100.47 and a beta of 2.03. 10x Genomics has a twelve month low of $13.58 and a twelve month high of $102.81. The firm has a 50-day simple moving average of $74.06 and a two-hundred day simple moving average of $41.41.

10x Genomics (NASDAQ:TXG - Get Free Report) last posted its earnings results on Thursday, November 5th. The company reported ($0.15) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.27) by $0.12. 10x Genomics had a negative net margin of 12.18% and a negative return on equity of 9.33%. The firm had revenue of $150.67 million during the quarter, compared to analysts' expectations of $147.96 million. During the same period in the previous year, the business posted ($0.22) EPS. The business's revenue was up 1.1% compared to the same quarter last year. Research analysts expect that 10x Genomics will post -0.77 EPS for the current fiscal year.

Insider Buying and Selling

In other 10x Genomics news, Director Shehnaaz Suliman sold 5,723 shares of the stock in a transaction that occurred on Tuesday, September 22nd. The stock was sold at an average price of $81.19, for a total transaction of $464,650.37. Following the completion of the transaction, the director owned 23,792 shares of the company's stock, valued at $1,931,672.48. This represents a 19.39% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Serge Saxonov sold 25,000 shares of the firm's stock in a transaction that occurred on Tuesday, September 22nd. The shares were sold at an average price of $81.22, for a total value of $2,030,500.00. Following the completion of the transaction, the chief executive officer owned 1,050,249 shares in the company, valued at approximately $85,301,223.78. This trade represents a 2.33% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 179,333 shares of company stock worth $11,810,070 in the last quarter. 8.84% of the stock is owned by insiders.

Hedge Funds Weigh In On 10x Genomics

A number of institutional investors have recently bought and sold shares of TXG. Farther Finance Advisors LLC lifted its holdings in 10x Genomics by 29.9% during the 3rd quarter. Farther Finance Advisors LLC now owns 934 shares of the company's stock worth $84,000 after buying an additional 215 shares in the last quarter. GAMMA Investing LLC grew its stake in shares of 10x Genomics by 8.7% in the third quarter. GAMMA Investing LLC now owns 4,668 shares of the company's stock worth $422,000 after acquiring an additional 374 shares in the last quarter. Arizona State Retirement System grew its stake in shares of 10x Genomics by 1.5% in the second quarter. Arizona State Retirement System now owns 29,223 shares of the company's stock worth $1,120,000 after acquiring an additional 430 shares in the last quarter. Carolina Wealth Advisors LLC purchased a new stake in shares of 10x Genomics during the third quarter worth $46,000. Finally, Allspring Global Investments Holdings LLC increased its position in shares of 10x Genomics by 3.4% during the third quarter. Allspring Global Investments Holdings LLC now owns 16,229 shares of the company's stock worth $1,440,000 after acquiring an additional 539 shares during the period. 84.68% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about 10x Genomics

Here are the key news stories impacting 10x Genomics this week:

• Positive Sentiment: 10x Genomics reported a Q3 loss of $0.15 per share, narrower than analysts’ estimate of $0.27, while revenue of $150.7 million topped expectations of $148.0 million. 10x Genomics Q3 results
• Positive Sentiment: The company raised its 2026 revenue forecast to $625 million–$635 million, above the roughly $620 million consensus. Management cited Atera demand and spatial consumables growth, and targets about 50 Atera shipments by year-end. Q3 earnings call highlights
• Positive Sentiment: 10x launched Sentira Single Cell, a Claude-powered AI tool designed to simplify cell-data analysis. The product could make research workflows easier and create recurring revenue opportunities. Sentira AI tool launch
• Neutral Sentiment: Citi raised its price target to $60 but maintained a Neutral rating, suggesting a somewhat improved view without a shift to a bullish recommendation. Citi price-target update
• Negative Sentiment: Management flagged production constraints and margin pressure as ongoing challenges, which could limit the benefits of stronger demand and growth. Q3 earnings call highlights
• Negative Sentiment: UBS cut its price target to $61 from $90 and kept a Neutral rating, signaling reduced expectations despite the raised company outlook. UBS price-target update

10x Genomics Company Profile

10x Genomics, Inc is a life sciences technology company that develops tools for analyzing biological systems at the single-cell and spatial levels. Its technologies are designed to help researchers study gene expression, cellular interactions, tissue organization and other biological processes in greater detail than conventional laboratory methods.

The company's product portfolio includes the Chromium platform for single-cell analysis, the Visium platform for spatial transcriptomics, and the Xenium platform for high-resolution in situ analysis of tissue samples.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.